Moderna (MRNA) experienced significant change in its mRNA vaccine business line in the past year. The company's share price reflected such, recording a 96% jump. Moderna simultaneously reached a settlement for a patent dispute regarding COVID-19 vaccine, agreeing to play $2.25 billion. In a turn of events, the FDA initially refused to review Moderna's mRNA flu vaccine application, but later reversed its decision agreeing to review and consider the same. Amidst changes and disruptions of global magnitude, the FDA's approach to Moderna stirred some controversy. Moderna's stock price reflected the company's dynamic status, influenced by events such as FDA's decisions and the shift in company's focus to oncology treatments through Moderna 2.0. Even in this climate of innovation and redirecting efforts, MRNA shares dipped 6.6%, which came unexpectedly in light of the anticipated beneficial impact on cancer treatment. Analysts however provided a mixed forecast, with most recommending a 'Reduce' position, yet Barclays analyst anticipated a positive slope raising the price target for MRNA to $48.0. The decision to review the mRNA flu shot application was seen by majority in the industry as a significant turning point, influencing the valuation and market direction of MRNA.
Moderna MRNA News Analytics from Thu, 30 Oct 2025 07:00:00 GMT to Sat, 04 Apr 2026 08:07:27 GMT -
Rating 3
- Innovation 8
- Information 9
- Rumor -4
